The assessment of angiogenic factors VEGF, VEGFR-2 and VCAM-1 in the serum of women with malignant ovarian tumours before and after the menopause;Ocena steżeń czynników angiogennych VEGF, VEGFR-2 i VCAM-1 w surowicy krwi kobiet z nowotworami złośliwymi jajnika przed i po menopauzie

Przeglad Menopauzalny

Volumn 6, Issue 3, 2007, Pages 128-133

  Czekierdowski, Artur ^a   Czekierdowska, Sylwia ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Angiogenic cytokines; Menopausal status; Ovarian cancer; VEGF; VEGFR

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; TUMOR MARKER; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CHI SQUARE TEST; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE EVALUATION; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION;

EID: 34547456579     PISSN: 16438876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Yancopoulos GD, Davis S, Gale NW, et al. Vascular specific growth factors and blood vessel formation. Nature 2000; 407: 242-8.
3. Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis Curr Top Microbiol Immunol 1999; 237: 97-132.
4. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11: 617-24.
5. Orre M, Rogers PA. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer 1999; 84: 101-8.
6. Tanir HM, Ozalp S, Yalcin OT, et al. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. Eur J Gynaecol Oncol 2003; 24: 271-4.
7. Artini PG, Cristello F, Monti M, et al. Vascular endothelial growth factor and its soluble receptor in ovarian pathology. Gynecol Endocrinol 2005; 21: 50-6.
8. Ohene-Abuakwa Y, Pignatelli M. Adhesion molecules as diagnostic tools in tumor pathology. Int J Surg Pathol 2000; 8: 191-200.
9. Byrne GJ, Bundred NJ. Surrogate markers of tumoral angiogenesis. Int J Biol Markers 2000; 15: 334-9.
10. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989; 59: 1203-11.
11. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-9.
12. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000; 92: 1329-36.
13. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006; 118: 879-88.
14. Tempfer C, Obermair A, Hefler L, et al. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol 1998; 92: 360-3.
15. Qiao XM, Wang ZM. Significance of concentration of serum soluble vascular cell adhesion molecule-1 in epithelial ovarian carcinoma. Ai Zheng 2004; 23: 81-4.
16. Fox SB, Turner GD, Leek RD, et al. The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. Breast Cancer Res Treat 1995; 36: 219-26.
17. Guerrero-Esteo M, Ruiz-Velasco N, Munoz M, Teixido J. Role of two conserved glycine residues in the beta-propeller domain of the integrin alpha4 subunit in VLA-4 conformation and function. FEBS Lett 1998; 429: 123-8.
18. Ding YB, Chen GY, Xia JG, et al. Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol 2003; 9: 1409-14.
19. Alexiou D, Karayiannakis AJ, Syrigos KN, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001; 37: 2392-7.
20. Giannoulis K, Angouridaki C, Fountzilas G, et al. Serum concentrations of soluble ICAM-1 and VCAM-1 in patients with colorectal cancer. Clinical implications. Tech Coloproctol 2004; 8: 65-7.
21. Czekierdowski A, Czekierdowska S, Stachowicz N, et al. Serum vascular cell adhesion molecule-1 (VCAM-1) concentration and 3D sonographic assessment of intratumoral blood flow in women with endometrial cancer. Pol J Environ Stud 2005; 14: 483-7.